MX2016016311A - Composición y método para el tratamiento de enfermedades neurológicas y lesión cerebral. - Google Patents
Composición y método para el tratamiento de enfermedades neurológicas y lesión cerebral.Info
- Publication number
- MX2016016311A MX2016016311A MX2016016311A MX2016016311A MX2016016311A MX 2016016311 A MX2016016311 A MX 2016016311A MX 2016016311 A MX2016016311 A MX 2016016311A MX 2016016311 A MX2016016311 A MX 2016016311A MX 2016016311 A MX2016016311 A MX 2016016311A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- composition
- neurological diseases
- cerebral injury
- combination
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000022306 Cerebral injury Diseases 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
Abstract
Metodos y composiciones que incluyen o incluyen la administracion de un farmaco hidrofobo, un profarmaco del mismo, una sal del mismo, una isoforma del mismo, o una combinacion de los mismos; ciclodextrina, un profarmaco de la misma, una sal de la misma, o una combinacion de los mismos; polietilenglicol, propilenglicol, o una combinacion de los mismos: y opcionalmente, un vehiculo farmaceuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011553P | 2014-06-12 | 2014-06-12 | |
| PCT/US2015/035438 WO2015191931A1 (en) | 2014-06-12 | 2015-06-11 | Composition and method for the treatment of neurological diseases and cerebral injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016016311A true MX2016016311A (es) | 2017-10-12 |
Family
ID=54834361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016311A MX2016016311A (es) | 2014-06-12 | 2015-06-11 | Composición y método para el tratamiento de enfermedades neurológicas y lesión cerebral. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10413517B2 (es) |
| EP (1) | EP3154535A4 (es) |
| JP (1) | JP6632999B2 (es) |
| KR (1) | KR20170012555A (es) |
| AU (1) | AU2015274462A1 (es) |
| CA (1) | CA2951912A1 (es) |
| IL (1) | IL249439A0 (es) |
| MX (1) | MX2016016311A (es) |
| WO (1) | WO2015191931A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017242544B2 (en) * | 2016-03-31 | 2022-11-24 | Midatech Ltd. | Cyclodextrin-panobinostat adduct |
| MX2019000342A (es) * | 2016-07-08 | 2019-09-04 | Ranedis Pharmaceuticals Llc | Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas. |
| US11219608B2 (en) | 2017-12-04 | 2022-01-11 | Northwestern University | Triple combination formulation for treatment of chronic pain |
| CA3114021C (en) * | 2018-10-29 | 2025-05-27 | Cyclo Therapeutics, Inc. | METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE |
| CR20220325A (es) | 2019-12-20 | 2022-08-19 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazoles y sus usos |
| EP4208189A4 (en) * | 2020-09-03 | 2024-08-07 | University of Notre Dame du Lac | THERAPY TO STIMULATE HIPPOCAMPAL NEURAL PROGENITORS AND NEUROGENESIS IN ADULTS |
| KR20240016950A (ko) | 2021-05-04 | 2024-02-06 | 테나야 테라퓨틱스, 인코포레이티드 | 대사 질환 및 hfpef의 치료에 사용하기 위한 2-플루오로알킬-1,3,4-옥사디아졸-5-일-티아졸, hdac6 억제제 |
| EP4333806A1 (en) * | 2021-05-06 | 2024-03-13 | Spepharm Ag | Pharmaceutical formulations |
| CN115015412B (zh) * | 2022-05-26 | 2024-07-05 | 江苏独步生物科技有限公司 | 一种与中枢神经损伤修复相关的分子靶标及其应用 |
| CN114931630B (zh) * | 2022-07-11 | 2024-08-30 | 齐鲁制药有限公司 | 一种皮下注射用神经节苷脂组合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE312609T1 (de) * | 1994-04-22 | 2005-12-15 | Pentech Pharmaceuticals Inc | Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz |
| BRPI0610128B1 (pt) | 2005-05-13 | 2021-12-07 | Topotarget Uk Limited | Composição farmacêutica, e, uso de uma composição |
| US7575876B2 (en) | 2005-10-27 | 2009-08-18 | The University Of Washington | Biomarkers for neurodegenerative disorders |
| US20090012148A1 (en) | 2005-11-01 | 2009-01-08 | Maxfield Frederick R | Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis |
| KR100917809B1 (ko) * | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
| CN101528212A (zh) * | 2006-09-28 | 2009-09-09 | 默克公司 | Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物 |
| CA2679629A1 (en) * | 2007-02-27 | 2008-09-04 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
| WO2010138802A2 (en) | 2009-05-28 | 2010-12-02 | Cornell University | Compositions and their use for removing cholesterol |
| US20110195488A1 (en) | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Devices for collection and stabilization of biomarkers in liquid samples |
| US20110237832A1 (en) | 2010-03-29 | 2011-09-29 | University Of Notre Dame Du Lac | Synthesis of hdac inhibitors: trichostatin a and analogues |
| US9233097B2 (en) * | 2010-08-05 | 2016-01-12 | Siga Technologies, Inc. | ST-246 liquid formulations |
| TWI544922B (zh) * | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| JP2015524444A (ja) | 2012-08-03 | 2015-08-24 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ライソゾーム蓄積症を治療するためのシクロデキストリン |
| WO2015042326A2 (en) | 2013-09-18 | 2015-03-26 | University Of Notre Dame Du Lac | Methods for detection and treatment of neurodegenerative diseases |
-
2015
- 2015-06-11 MX MX2016016311A patent/MX2016016311A/es unknown
- 2015-06-11 WO PCT/US2015/035438 patent/WO2015191931A1/en not_active Ceased
- 2015-06-11 AU AU2015274462A patent/AU2015274462A1/en not_active Abandoned
- 2015-06-11 US US14/737,473 patent/US10413517B2/en active Active
- 2015-06-11 CA CA2951912A patent/CA2951912A1/en not_active Abandoned
- 2015-06-11 KR KR1020177000640A patent/KR20170012555A/ko not_active Withdrawn
- 2015-06-11 EP EP15807054.0A patent/EP3154535A4/en not_active Withdrawn
- 2015-06-11 JP JP2016571225A patent/JP6632999B2/ja not_active Expired - Fee Related
-
2016
- 2016-12-07 IL IL249439A patent/IL249439A0/en unknown
-
2019
- 2019-08-19 US US16/544,783 patent/US20200179313A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6632999B2 (ja) | 2020-01-22 |
| IL249439A0 (en) | 2017-02-28 |
| US20200179313A1 (en) | 2020-06-11 |
| US20150359762A1 (en) | 2015-12-17 |
| EP3154535A1 (en) | 2017-04-19 |
| JP2017517528A (ja) | 2017-06-29 |
| US10413517B2 (en) | 2019-09-17 |
| WO2015191931A1 (en) | 2015-12-17 |
| AU2015274462A1 (en) | 2016-12-22 |
| CA2951912A1 (en) | 2015-12-17 |
| KR20170012555A (ko) | 2017-02-02 |
| EP3154535A4 (en) | 2018-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016016311A (es) | Composición y método para el tratamiento de enfermedades neurológicas y lesión cerebral. | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| MY199131A (en) | Human plasma kallikrein inhibitors | |
| HK1245634A1 (zh) | 作为egfr调节剂的取代的2-苯胺基嘧啶衍生物 | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MY190835A (en) | Bicyclic heterrocyclic derivatives as bromodomain inhibitors | |
| NZ725044A (en) | Compounds and compositions for inducing chondrogenesis | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| PH12017500602A1 (en) | Methods for treating ocular conditions | |
| PH12016501483B1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| IL261278A (en) | Pharmaceutical compositions for the treatment of cancer | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| SG10201902499VA (en) | Therapeutic nanoparticles and related compositions, methods and systems | |
| EA201892311A1 (ru) | Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга | |
| PH12016502235A1 (en) | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| EP3471775A4 (en) | HEMOGLOBIN-TARGETED DRUG ADMINISTRATION FOR CANCER TREATMENT | |
| EP3322435A4 (en) | Pharmaceutical compositions useful for the treatment of tissue injury | |
| MX2017008931A (es) | Formulaciones farmaceuticas de xantina o derivados de xantina. | |
| MX2017008655A (es) | Derivados de jasmonato y composiciones de los mismos. | |
| MX2019008847A (es) | Profarmacos de cisteamina. | |
| IL257689A (en) | Pharmacological preparations and methods for the treatment of diseases associated with hypoxia |